Accelerating drug development using biomarkers: A case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes

AAPS Journal

Volumn 10, Issue 2, 2008, Pages 401-409

  Krishna, Rajesh ^a   Herman, Gary ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Disease progression; Distal biomarkers; DPP4; Glucose; Proximal biomarkers; Sitagliptin; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETOGENESIS; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; WEIGHT GAIN;

ANIMALS; ANTIGENS, CD26; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; PYRAZINES; TRIAZOLES;

EID: 53849137996     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9041-8     Document Type: Review

References (48)

1. I. Kola, and J. Landis. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3 (8):711-5 (2004).
2. B. H. Littman, and S. A. Williams. The ultimate model organism: Progress in experimental medicine. Nature Rev. Drug Discov. 4 (8):631-8 (2005).
3. R. Krishna. Introduction to dose optimization. In R. Krishna (ed.), Dose optimization in drug development, Taylor and Francis, v161, 2006, pp. 1-13.
4. R. Krishna. Quantitative clinical pharmacology: Making paradigm shifts a reality. J. Clin. Pharmacol. 46 (9):966-7 (2006).
5. C. -P. Milne. US and European regulatory initiatives to improve R&D performance. Expert Opinion on Drug Discovery. 1 (1):11-4 (2006).
6. K. I. Kaitin. Decline in drug approvals is driving industry, FDA to enhance efficiency. Tufts Center for the Study of Drug Development Impact Report. 7 (1) (2005)Jan/Feb.
7. Challenge and opportunity on the critical path to new medical products, US Food and Drug Administration, 2004. Available at: http://www.fda.gov/ oc/initiatives/criticalpath/whitepaper.html. Accessed December 29, 2006.
8. Innovative medicines for Europe, EFPIA, 2004. Available at: http://ec.europa.eu/research/fp6/index_en.cfm?p=1_innomed. Accessed December 29, 2006.
9. J. A. Wagner. Bridging preclinical and clinical development - biomarker validation and qualification. In R. Krishna (ed.), Dose Optimization in Drug Development, Informa Healthcare, New York, 2006, pp. 35-43.
10. J. A. Wagner, S. A. Williams, and C. J. Webster. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 81 (1):104-7 (2007).
11. Biomarkers Definitions Working R. Group. Biomarkers and surrogate endpoints in clinical trials: Proposed definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89-95 (2001).
12. P. Zimmet, K. G. Alberti, and J. Shaw. Global and societal implications of the diabetes epidemic. Nature. 414: 782-87 (2001).
13. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 27: 1047-53 (2004).
14. J. R. Sowers. Obesity as a cardiovascular risk factor. Amer. J. Med. 115 (Suppl 8A):37S-41S (2003).
15. R. A. DeFronzo. The triuAvirate: Beta-cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes. 37: 667-87 (1988).
16. D. Tripathy, K. F. Eriksson, M. Orho-Melander, J. Fredriksson, G. Ahlqvist, and L. Groop. Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes. Diabetologia. 47: 782-93 (2004).
17. G. C. Weir, and S. Bonner-Weir. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 53 (Suppl 3):S16-21 (2004), Dec.
18. A. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52: 102-10 (2003).
19. G. Jiang, and B. Zhang. Glucagon and regulation of glucose metabolism. Amer. J. Physiol. Endocrinol. Metab. 284: 671-8 (2003).
20. T. Vilsboll, T. Krarup, C. F. Deacon, S. Madsbad, and J. J. Holst. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 50: 609-13 (2001).
21. T. Vilsboll, F. K. Knop, T. Krarup, A. Johansen, S. Madsbad, S. Larsen, T. Hansen, O. Pedersen, and J. J. Holst. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J. Clin. Endo. and Metabol. 88: 4897-903 (2003).
22. M. Zander, S. Madsbad, J. L. Madsen, and J. J. Holst. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet. 359: 824-30 (2002).
23. B. Rolin, M. O. Larsen, C. F. Gotfredsen, C. F. Deacon, R. D. Carr, M. Wilken, and L. B. Knudsen. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 283 (4):E745-52 (2002).
24. M. A. Nauck, M. Hompesch, R. Filipczak, T. D. Le, M. Zdravkovic, and J. Gumprecht. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes. 114 (8):417-23 (2006).
25. M. A. Nauck, S. Duran, D. Kim, D. Johns, J. Northrup, A. Festa, R. Brodows, M. Trautmann. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia. 50(2):259-267 (2007).
26. S. A. Doggrell. Recent evidence of sustained benefit with exenatide in Type 2 diabetes. Expert Opin. Pharmacother. 7 (14):2003-6 (2006).
27. D. J. Drucker, and M. A. Nauck. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368 (9548):1696-705 (2006).
28. M. K. Reimer, J. J. Holst, and B. Ahren. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. 146 (5):717-27 (2002), May.
29. D. Kim, L. Wang, M. Beconi, G. J. Eiermann, M. H. Fisher, H. He, G. J. Hickey, J. E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M. E. McCann, R. A. Patel, A. Petrov, G. Scapin, S. B. Patel, R. S. Roy, J. K. Wu, M. J. Wyvratt, B. B. Zhang, L. Zhu, N. A. Thornberry, and A. E. Weber. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48(1):141-51 (2005), Jan 13.
30. D. Marguet, L. Baggio, T. Kobayashi, A. M. Bernard, M. Pierres, P. F. Nielsen, U. Ribel, T. Watanabe, D. J. Drucker, and N. Wagtmann. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. PNAS. 97: 6874-9 (2000).
31. B. Ahren, M. Landin-Olsson, P. A. Jansson, M. Svensson, D. Holmes, and A. Schweizer. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89: 2078-2084 (2004).
32. S. Ristic, S. Byiers, J. Foley, and D. Holmes. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obese Metab. 7 (6):692-8 (2005).
33. G. A. Herman, C. Stevens, K. Van Dyck, A. Bergman, B. Yi, M. De Smet, K. Snyder, D. Hilliard, M. Tanen, W. Tanaka, A. Q. Wang, W. Zeng, D. Musson, G. Winchell, M. J. Davies, S. Ramael, K. Gottesdiener, and J. A. Wagner. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol. Ther. 78 (6):675-88 (2005).
34. R. E. Pratley, S. Jauffret-Kamel, E. Galbreath, and D. Holmes. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab. Res. 38 (6):423-8 (2006).
35. J. Rosenstock, R. Brazg, P. J. Andryuk, K. Lu, and P. Stein. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 28 (10):1556-68 (2006).
36. G. A. Herman, A. Bergman, F. Liu, C. Stevens, A. Q. Wang, W. Zeng, L. Chen, K. Snyder, D. Hilliard, M. Tanen, W. Tanaka, A. G. Meehan, K. Lasseter, S. Dilzer, R. Blum, and J. A. Wagner. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J. Clin. Pharmacol. 46 (8):876-86 (2006).
37. G. A. Herman, A. Bergman, C. Stevens, P. Kotey, B. Yi, P. Zhao, B. Dietrich, G. Golor, A. Schrodter, B. Keymeulen, K. C. Lasseter, M. S. Kipnes, K. Snyder, D. Hilliard, M. Tanen, C. Cilissen, M. De Smet, I. de Lepeleire, K. Van Dyck, A. Q. Wang, W. Zeng, M. J. Davies, W. Tanaka, J. J. Holst, C. F. Deacon, K. M. Gottesdiener, and J. A. Wagner. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91 (11):4612-9 (2006).
38. A. Bergman, C. Stevens, Y. Zhou, B. Yi, M. De Smet, K. Snyder, D. Hilliard, M. Tanen, W. Tanaka, A. Q. Wang, W. Zeng, D. Musson, G. Winchell, M. J. Davies, S. Ramael, K. Gottesdiener, J. A. Wagner, and G. A. Herman. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin. Ther. 28 (1):55-72 (2006).
39. G. R. Lankas, B. Leiting, R. S. Roy, G. J. Eiermann, M. G. Beconi, T. Biftu, C. C. Chan, S. Edmondson, W. P. Feeney, H. He, D. E. Ippolito, D. Kim, K. A. Lyons, H. O. Ok, R. A. Patel, A. N. Petrov, K. A. Pryor, X. Qian, L. Reigle, A. Woods, J. K. Wu, D. Zaller, X. Zhang, L. Zhu, A. E. Weber, and N. A. Thornberry. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 54 (10):2988-94 (2005).
40. B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P. A. Jansson, M. Sandqvist, P. Bavenholm, S. Efendic, J. W. Eriksson, S. Dickinson, and D. Holmes. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 25: 869-875 (2002).
41. B. Ahren, R. Gomis, E. Standl, D. Mills, and A. Schweizer. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 27: 2874-2880 (2004).
42. R. Scott, M. Wu, M. Sanchez, P. Stein. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract. 2006 Dec 5.
43. M. A. Nauck, M. M. Heimesaat, K. Behle, J. J. Holst, M. S. Nauck, R. Ritzel, M. Hufner, and W. H. Schmiegel. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endo. Metab. 87: 1239-46 (2002).
44. B. Sudre, P. Broqua, R. B. White, D. Ashworth, D. M. Evans, R. Haigh, J. L. Junien, and M. L. Aubert. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes. 51: 1461-69 (2002).
45. J. Mu, J. Woods, Y. P. Zhou, R. S. Roy, Z. Li, E. Zycband, Y. Feng, L. Zhu, C. Li, A. C. Howard, D. E. Moller, N. A. Thornberry, and B. B. Zhang. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of Type 2 diabetes. Diabetes. 55 (6):1695-704 (2006).
46. B. Ahren, G. Pacini, J. E. Foley, and A. Schweizer. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 28 (8):1936-40 (2005).
47. A. Mari, W. M. Sallas, Y. L. He, C. Watson, M. Ligueros-Saylan, B. E. Dunning, C. F. Deacon, J. J. Holst, and J. E. Foley. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 90 (8):4888-94 (2005).
48. K. I. Kaitin. Fastest drug developers consistently best peers on key performance metrics. Tufts Center for the Study of Drug Development Impact Report 2006 Sep/Oct;8(5).